China's first "antibody drug coupled treatment of malignant tumor clinical application expert consensus" released

On December 5, China's first "Expert Consensus on Clinical Application of Antibody Drug Associations for the Treatment of Malignant Tumors" was released at the "National Cancer Center Clinical Research Summit Forum and the Annual Meeting of the Chinese Cancer Society's Clinical Research Committee on Cancer Drugs" and will be published in the Chinese Journal of Oncology in January next year.
The consensus was jointly initiated by the National Cancer Center, Professor Xu Binghe, Director of the Drug Clinical Trials Research Center of the Beijing Concord Medical College of the Chinese Academy of Medical Sciences, the Professional Committee of Clinical Research on Cancer Drugs of the Chinese Anti-Cancer Association, the National Committee of Experts on Clinical Application Monitoring of Anti-Tumor Drugs, the National Committee of Breast Cancer Experts of the National Cancer Quality Control Center, and the Committee of Experts on The Quality Control and Improvement of Cancer Treatment in Beijing.Professor Xu Binghe
According to Professor Xu Binghe, antibody drug coupled (ADC) is a class of linked cytotoxic drugs to monoclonal antibodies targeted biological agents, such drugs can not only inhibit the tumor signaling pathway, but also directly kill tumor cells, but also very accurate killing. In recent years, ADC drugs have been one of the most popular research topics in the field of precision tumor therapy. "ADC drugs are relatively new, we are not very familiar with this type of drugs, the consensus is to solve the role of these drugs mechanisms, adaptive and clinical scope of application, and strengthen its safety management, because ADC drugs not only in breast cancer, urological tumors, stomach cancer, lymphoma and other fields have many breakthrough development results."
From the consensus, we can see that there are currently 8 kinds of ADC drugs approved in the world, China has 2 kinds of approved, one is approved in January this year, Enmetro-Zhu single resistance, is also china's first approved listed ADC drugs, it is used for HER-2 positive advanced breast cancer second-line treatment, as well as anti-After the new ancillary treatment of HER-2, breast cancer is still a secondary treatment with residual lesions, and the second is the Virbutoxidan, approved in May, for the treatment of classic Hodgkin's lymphoma, systemic mesolytic large cell lymphoma, etc., which brings new hope to patients with refractic lymphoma.
Professor Xu Binghe said: "Oncology treatment is a multidisciplinary combination of treatment, including traditional oncology, surgery, radiotherapy, but also imaging, diagnosis, pathology, pharmacy and nursing teams, mental health teams and other teams involved. In formulating the consensus, we invited Professor Li Guohui, Director of The Pharmacy Department of the Oncology Hospital of the Chinese Academy of Medical Sciences, because we need to listen to the recommendations of the Pharmacy Department in guiding the use of medicines, and pharmacists should participate in such work as house inspection to make the use of drugs more rational and safer. ADC drugs also face multidisciplinary cooperation after the market, such as how to choose the right population, the right timing of medication, with radiotherapy or other treatment methods how to cooperate organically, the combination of treatment order, these need to be addressed by multidisciplinary team, multidisciplinary cooperation is aimed at further improving the effectiveness of cancer drug treatment, reduce adverse reactions. "
。